作者
Zein Assad,Anne‐Sophie Romain,Camille Aupiais,Mickaël Shum,Cécile Schrimpf,Mathie Lorrot,Harriet Corvol,Blandine Prévost,Charlène Ferrandiz,Anna Giolito,Zaba Valtuille,Matthieu Bendavid,Jérémie F. Cohen,Julie Toubiana,Loïc de Pontual,Camille F. Delande,Michael L. Levy,Perrine See,Robert Cohen,Corinne Lévy,François Angoulvant,Léa Lenglart,Maud Gits‐Muselli,Valérie Biran,Kadiatou Diallo,Oluwafunmilola Alemede,Mohamed M. El Hebil,Xavier Durrmeyer,Géraldine Labouret,Natacha Casanovas,Benjamin Hallak,Olympe Maréchal,Camille Jung,C. Bréhin,Naïm Ouldali
摘要
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.
爱静静
zzzyyy
乐乐乐乐乐乐
浅尝离白
shinysparrow
kento
愤怒的豆腐人
景辣条
竹筏过海
YifanWang
寻道图强
研友_ZAVbe8
鬼见愁
徐叽钰
华仔
睡觉晒太阳
不配.
mmyhn
吃不饱星球球长
sirius
皖公网安备34019202002308
